JPS6251618A - Virus inactivator - Google Patents

Virus inactivator

Info

Publication number
JPS6251618A
JPS6251618A JP19126285A JP19126285A JPS6251618A JP S6251618 A JPS6251618 A JP S6251618A JP 19126285 A JP19126285 A JP 19126285A JP 19126285 A JP19126285 A JP 19126285A JP S6251618 A JPS6251618 A JP S6251618A
Authority
JP
Japan
Prior art keywords
virus
aldose
hours
arylcarbamoylaldose
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP19126285A
Other languages
Japanese (ja)
Other versions
JPH03842B2 (en
Inventor
Naoki Kashiwamura
直樹 柏村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JNC Corp
Original Assignee
Chisso Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chisso Corp filed Critical Chisso Corp
Priority to JP19126285A priority Critical patent/JPS6251618A/en
Publication of JPS6251618A publication Critical patent/JPS6251618A/en
Publication of JPH03842B2 publication Critical patent/JPH03842B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

PURPOSE:A virus inactivator, containing a novel O-arylcarbamoylaldose as an active constituent, having oxgen radical forming ability and virus inactivating ability and capable of exhibiting nucleic acid cleaving action in vitro. CONSTITUTION:A virus inactivator obtained by using preferably an O- aralcarbamoylaldose having pentasaccharide and hexasaccharide in the aldose part as an active constituent. The O-arylcarbamoylaldose has nucleic acid cleaving action and is capable of inactivating viruses, e.g. tobacco mosaic virus or bacteriophage phiX174, in vitro. The O-arylcarbamoylaldose can be obtained by reacting aldose with an aryl isocyanate in a solvent. Specific examples thereof include compounds expressed by formulas I, II, etc.

Description

【発明の詳細な説明】 本発明はウィルス不活化能を有するアルドース誘導体(
=関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention provides an aldose derivative (
= related.

さら(−詳しくはウィルス不活化能を有する9−アリー
ルカルバモイル基で置換されたアルドース(=関する。
Further (-specifically, it relates to an aldose substituted with a 9-arylcarbamoyl group having virus inactivation ability).

近年ウィルス不活化剤として核酸を切断する化合物(:
関する研究が盛んとなり、これまで(ユ簡単な化合物と
しては過酸化物、キノン、メルカプタンなどが提案され
ているが、未だ充分な効果を挙げるζ二は至っていない
In recent years, compounds that cleave nucleic acids as virus inactivators (:
Research on this topic has become active, and simple compounds such as peroxides, quinones, and mercaptans have been proposed, but no one has yet achieved sufficient effects.

本発明者らは、ウィルスの本体を形成する核酸が酸素ラ
ジカル1:よって切断されること(二着目して酸素ラジ
カル生成能を有する化合物として、それ自体には酸素ラ
ジカル生成能を有しないアルドースを基本化合物として
その誘導体(二つき鋭意研究を行い、核酸切断作用を有
する、すなわちウィルス不活化能を有する、新規な誘導
体を見出し、本発明1;至った。
The present inventors discovered that the nucleic acids that form the main body of the virus are cleaved by oxygen radicals (secondary focus is on aldose, which itself does not have the ability to generate oxygen radicals, as a compound that has the ability to generate oxygen radicals). As a basic compound, we conducted extensive research on derivatives thereof, and found a new derivative that has a nucleic acid cleaving action, that is, an ability to inactivate viruses, and thus the present invention 1 was achieved.

即ち、本発明は9−アリールカルバモイルアルドースを
有効成分とするウィルス不活化剤を要旨とするものであ
る。
That is, the gist of the present invention is a virus inactivating agent containing 9-arylcarbamoylaldose as an active ingredient.

この誘導体は酸素ラジカル生成能を有し、またインヴイ
トロ(ムn vitro )で核酸切断作用を示すこと
が明らかとなった。
It has been revealed that this derivative has the ability to generate oxygen radicals and exhibits a nucleic acid cleaving action in vitro.

更(二この誘導体のタバコモザイクウィルス及びバクテ
リ−オファ−ジ−X1フ4i二対する不活化作用をイン
ヴイトロで検し、有効であることが明らかとなった。
Furthermore, the inactivating effect of these two derivatives on tobacco mosaic virus and bacterium ophage X1F4i was tested in vitro, and it was found to be effective.

本発明における9−アリールカルバモイルアルドースの
アルドース部は5炭糖又は6炭糖であることが好ましい
The aldose moiety of the 9-arylcarbamoyl aldose in the present invention is preferably a pentose or a hexose.

またこのアルドースは一級アルコール部分の酸化物、例
えばグルクロン酸を含む概念である。
Moreover, this aldose is a concept that includes an oxide of a primary alcohol moiety, such as glucuronic acid.

本発明におけるq−アリールカルバモイルアルドースを
例えば5炭糖について式示すれば次のようである。但し
本式は、フィッシャーの式示によるものではない。
The formula of q-arylcarbamoylaldose in the present invention, for example, for pentose sugar is as follows. However, this formula is not based on Fisher's formula.

H−C=0 H−C−R’ H−C−R” ■ H−C−R3 几4 ここζ:R1、B2及びR3はOH又は−0CO−NH
−Aを表ワシ、R’ )j −CH20H、−COOH
又バーCH,0CO−NH−Aを表わし、R1からB4
迄は全体として少なくとも1つの一0CO−NH−Aを
含み、人はアリール基を表わす。このアリール基Aの例
としてはフェニル基、ナフチル基、およびそれらのベン
ゼン核b○Hが置換された基を挙げることができる。
H-C=0 H-C-R'H-C-R" ■ H-C-R3 几4 Here ζ: R1, B2 and R3 are OH or -0CO-NH
-A is the front side, R')j -CH20H, -COOH
Also represents bar CH,0CO-NH-A, R1 to B4
The whole group includes at least one CO-NH-A and represents an aryl group. Examples of the aryl group A include a phenyl group, a naphthyl group, and a group in which the benzene nucleus b○H thereof is substituted.

また例えば6炭糖(二ついて式示すれば次のようである
。但し本式はフィッシャーの式示(=よるものではない
For example, the formula for six carbon sugars is as follows. However, this formula is not based on Fisher's formula (=).

H−(、−0 H−C−1’L’ H−C−R’ H−C−R’ H−C−R” ここ1’:、R’ 、R’ 、R’及びR8はOH又は
−0CO−正一人を表わし、R9は一■pH、−COO
H又は−OH,−000−N)I−A ヲ表ワL、、R
’カラR’マテハ全体として少なくとも1つの一〇〇〇
−NH−Aを含み人は上記のものと同じ意味を表わす。
H-(,-0 H-C-1'L'H-C-R'H-C-R'H-C-R" where 1':, R', R', R' and R8 are OH or -0CO- represents one positive person, R9 is one pH, -COO
H or -OH, -000-N) I-A wo table L,,R
'Kala R' Mateha as a whole contains at least one 1000-NH-A and has the same meaning as above.

本発明C:おける9−アリールカルバモイルアルドース
を合成する(二は適当な溶媒中でアルドース(ニアリル
イソンアネートを反応させること(二より達することが
できる。
The present invention C: synthesizes the 9-arylcarbamoyl aldose (2 can be achieved by reacting the aldose (nyallylisonanate) in a suitable solvent (2).

アルドースの特定の部位をカルバモイル化する場合C:
は、まずカルバモイル化すべき部位の水酸基を定め、■
その他の反応性水酸基を保護し・■適当な溶媒中でアリ
ルイソンアネートを反応させ、■保護された生成物を分
取し・■保護基を離脱させ、ついで■生成物を分離、精
製する。
When carbamoylating a specific site of aldose C:
First, determine the hydroxyl group at the site to be carbamoylated, and
Protect other reactive hydroxyl groups, ■ React with allylisonanate in a suitable solvent, ■ Separate the protected product, ■ Remove the protecting group, and then ■ Separate and purify the product. .

カルバモイル化を望まない水酸基の保護の目的(=はエ
ーテル化、アセタール化、エステル化、分子内ラクトン
化などのいずれも使用可能であるが、アセタール化特C
:インプロビリデンアセタール化(アセトニド化)、分
子内ラクトン化が取扱い上有利であり、また後続のシリ
カゲルクロマトグラフィー処理(二対して安定であると
いう利点がある。但し分子内ラクトン化はグルクロン酸
のようなアルドースの一級アルコール部分の酸化物の場
合のみ可能である。
For the purpose of protecting hydroxyl groups for which carbamoylation is not desired (= can be used for any of etherification, acetalization, esterification, intramolecular lactonization, etc., but acetalization special C
: Improvylidene acetalization (acetonidation) and intramolecular lactonization are advantageous in terms of handling, and they also have the advantage of being more stable than the subsequent silica gel chromatography treatment (2). However, intramolecular lactonization This is possible only in the case of oxides of the primary alcohol moiety of aldoses.

アリールイソンアネートとしてはフェニルイソンアネー
トーナフタレンイソンアネートおよびその核置換誘導体
を用いることができる。前記核置換誘導体の核置換基と
してはp−ニトロフェニル基、m−ニトロフェニル基、
o−=)ロフェニル基を挙げることができる。
As the arylisonanate, phenylisonanate naphthaleneisonanate and its nuclear substituted derivatives can be used. The nuclear substituents of the nuclear substituted derivatives include p-nitrophenyl group, m-nitrophenyl group,
o-=)lophenyl group may be mentioned.

イソンアネートシ:よるカルバメート化(二おCする溶
媒としてはカルバメート化反応C:無為の溶媒であれば
何でも使用可能であり、脂肪族炭化水素、脂環族炭化水
素、芳香族炭化水素、ピリジン等の塩基性芳香族化合物
を用いることができる。特(;前記塩基性芳香族化合物
では反応時間を短縮し得て有利である。
Carbamate formation with carbon dioxide (carbamate reaction C: Any solvent can be used as long as the solvent is free of aliphatic hydrocarbons, alicyclic hydrocarbons, aromatic hydrocarbons, and bases such as pyridine. A basic aromatic compound can be used. In particular, the basic aromatic compound is advantageous because the reaction time can be shortened.

前記溶媒中(:おけるアルドース(保護されたものを含
む)の濃度は1〜5t/10o−の範囲が好ましい。ア
リールイソンアネートの濃度は前記アルドース(二対し
て1.5〜2.0モル当量の範囲が好ましい。
The concentration of the aldose (including protected ones) in the solvent is preferably in the range of 1 to 5 t/10O-. The concentration of the arylisonanate is 1.5 to 2.0 mol per 2 Equivalent ranges are preferred.

前記カルバメート化反応は前記インンアネートがこわれ
−ないようC:するため乾燥した雰囲気中で行なうのが
好ましい。空気雰囲気化で行なってもよいが、N2のよ
うな不活性ガス中で行なうのが好ましい。
The carbamate formation reaction is preferably carried out in a dry atmosphere to prevent the inanate from being destroyed. Although it may be carried out in an air atmosphere, it is preferably carried out in an inert gas such as N2.

前記カルバメート化反応の温度は約10℃から溶媒の沸
点付近までにおいて行いうる。
The carbamate reaction can be carried out at a temperature of about 10° C. to around the boiling point of the solvent.

前記カルバメート化反応の圧力は常圧で行うことができ
るが、溶媒が蒸発しない範囲での減圧下で、又は加圧下
(=行ってもよい。
The carbamate-forming reaction can be carried out at normal pressure, but it may also be carried out under reduced pressure or under increased pressure within a range in which the solvent does not evaporate.

前記カルバメート化反応の時間は1時間以上24時間種
変とすることができるが、収率及び副反応抑制の観点か
ら5〜15時間程度が好ましい。
The carbamate reaction time can vary from 1 hour to 24 hours, but is preferably about 5 to 15 hours from the viewpoint of yield and suppression of side reactions.

保護された反応生成物の分離については、該反応生成物
の沸点が一般に高く、蒸留によっては分解するおそれが
あって分離し難いのでクロマトグラフィーによって分取
するのが好ましいこのクロマトグラフィーの充填剤とし
てはシリカゲル、アルミナ等の無機物又は多糖類を用い
うるが、シリカゲルを用いるのが効率的である溶出剤と
しては芳香族炭化水素とエステルとの混合系が適当であ
る。特にベンゼン−酢酸エチル系混合物が優れている。
Regarding the separation of the protected reaction product, it is preferable to separate it by chromatography because the boiling point of the reaction product is generally high and there is a risk of decomposition by distillation, so it is preferable to separate it by chromatography. Although inorganic substances such as silica gel and alumina or polysaccharides can be used, it is efficient to use silica gel.A mixed system of an aromatic hydrocarbon and an ester is suitable as an eluent. In particular, a benzene-ethyl acetate mixture is excellent.

保護基の脱離法としては、一般(:ジオキナンー塩酸混
液、60%酢酸、イオン交換樹脂等を用いうるが、イオ
ン交換樹脂の存在下(=おいてアセトン−水混合液で処
理するのが適当である。
As a method for removing the protecting group, a general method such as a dioquinane-hydrochloric acid mixture, 60% acetic acid, an ion exchange resin, etc. can be used, but it is appropriate to treat with an acetone-water mixture in the presence of an ion exchange resin. It is.

保護基を脱した生成物は前述の如くシリカゲルクロマト
グラフィーで分取、精製するのが好ましい。溶出剤とし
ては極性溶剤とアルコール類との組合わせが適当である
が、特(=クロロホルムーメタノール混合物が効率よく
用いることができる。
The product from which the protecting group has been removed is preferably separated and purified by silica gel chromatography as described above. As the eluent, a combination of a polar solvent and an alcohol is suitable, but a chloroform-methanol mixture can be used particularly efficiently.

以下に実施例を示すが、本発明はこれら(ユ限られるも
のではない。
Examples are shown below, but the present invention is not limited to these.

参考例1 (3−0−フェニルカルバモイル−H−グルコース(夏
)の合成〕 H−C=O H−C−OH H−C−OH ■ H20H 1,2,5,6−ジーO−イソプロピリデン−α−P−
グルコフラノース(7,Of )・無水ピリジン(30
−)、フェニルインンアネー)(14−)を攪拌しなが
ら、室温で15時間反応させた後、溶媒と過剰の試薬を
留去しへ生成物をさう(ニジリカゲルカラムクロマトグ
ラフィーC二かけ)ベンゼン:酢酸エチル(2o:lV
/V)混液で溶出を行い、TLCでR7o、+5(ベン
ゼン:酢酸エチル、5:IV/V)を示す1,2,5,
6−ジー9−イソプロピリデン−3−9−フェニルカル
バモイル−α一旦−グルコフラノース(ンラツプ;〔α
〕。+61°;νmax 3300%2980%173
0、−1)を98%の収量で得た。この化合物(5f)
を10%アセトン水溶液(Loom)にとかし、アンバ
ーライト(商標)IR120B(H+)(強酸性イオン
交換樹脂:H+型)(以下1几12QB(H+)Jと略
記する。)(3f )を加え、95℃、5時間攪拌した
後・樹脂をろ過し・ろ夜を減圧濃縮して得られたシロッ
プをシリカゲルカラムクロマトグラフィー(クロロホル
ム: )9./−ル、 20 : lj’/V)ニカけ
、TLC(クロロホルム:メタノール、 6 : l 
V/V)0.22の両分を集め、減圧濃縮し、結晶性の
目的物〔!〕を79%で得た。
Reference Example 1 (Synthesis of 3-0-phenylcarbamoyl-H-glucose (summer)) H-C=O H-C-OH H-C-OH ■ H20H 1,2,5,6-di-O-isopropylidene -α-P-
Glucofuranose (7,Of)・Anhydrous pyridine (30
-), phenylinane) (14-) was reacted at room temperature for 15 hours with stirring, and the solvent and excess reagent were distilled off. ) Benzene: Ethyl acetate (2o:lV
1,2,5, which shows R7o, +5 (benzene: ethyl acetate, 5: IV/V) by TLC.
6-di-9-isopropylidene-3-9-phenylcarbamoyl-α-glucofuranose (nrap; [α
]. +61°; νmax 3300% 2980% 173
0, -1) was obtained in 98% yield. This compound (5f)
Dissolve in a 10% acetone aqueous solution (Loom), add Amberlite (trademark) IR120B (H+) (strongly acidic ion exchange resin: H+ type) (hereinafter abbreviated as 1 liter 12QB(H+)J) (3f), After stirring at 95°C for 5 hours, the resin was filtered, and the residue was concentrated under reduced pressure. The resulting syrup was subjected to silica gel column chromatography (chloroform: )9. /-l, 20: lj'/V) Nikake, TLC (chloroform:methanol, 6: l
V/V) 0.22 were collected and concentrated under reduced pressure to obtain the crystalline target product [! ] was obtained in 79%.

m、p、  :  110〜120 ℃〔α)D:+1
9.6°〜+12#5゜y max (cm−1) :
 3500% 2900% 1720PMR(CDCI
!、)δ(ppm) : 5.9 (H−1)6.25
(H−3) 7.5(芳香族H) UV、2 max : l 93 nm (g 745
0)232 nm (g 1320) 元素分析(”13H1707N) : 計算値(イ)   実測値鴎 N   4.51    4.68 参考例2 (3−!2−(α−ナフチルカルバモイル)−P−グル
コース(1)の合成〕 H−C=0 H−C−OH H−C−OH OH20H 1,2,5,6−ジー9−インプロピリデン−α−♀−
グルコフラノース(6,5f )・無水ピリジン(40
m)・α−ナフチルイソンアネート(8,2d )を光
を連断して室温で5時間攪拌反応させた後、溶媒を減圧
下で留去し、生成したシロップをシリカゲルカラムクロ
マトグラフィー(ベンゼン:酢酸エチル、5:lV/V
)により分画精製し、几、 0.55の画分を集め、減
圧濃縮を行い・1,2,5.6−ジー9−インブロピア
ン−3−0−(α−ナフチルカルバモイル)−α−D−
グルコフラノース(ンラップ;〔α〕0+72  、ν
 max3300.2980.1780crn  。
m, p,: 110 to 120 °C [α) D: +1
9.6°~+12#5°y max (cm-1):
3500% 2900% 1720PMR (CDCI
! , ) δ (ppm): 5.9 (H-1) 6.25
(H-3) 7.5 (Aromatic H) UV, 2 max: l 93 nm (g 745
0) 232 nm (g 1320) Elemental analysis ("13H1707N): Calculated value (a) Actual value 驎N 4.51 4.68 Reference example 2 (3-!2-(α-naphthylcarbamoyl)-P-glucose ( Synthesis of 1)] H-C=0 H-C-OH H-C-OH OH20H 1,2,5,6-di-9-impropylidene-α-♀-
Glucofuranose (6,5f)・Anhydrous pyridine (40
After stirring and reacting α-naphthylisonanate (8,2d) at room temperature for 5 hours with continuous light, the solvent was distilled off under reduced pressure, and the resulting syrup was subjected to silica gel column chromatography (benzene column chromatography). :Ethyl acetate, 5:lV/V
), 0.55 fractions were collected and concentrated under reduced pressure to give 1,2,5.6-di-9-imbropian-3-0-(α-naphthylcarbamoyl)-α-D. −
Glucofuranose (nrap; [α]0+72, ν
max3300.2980.1780crn.

PMル(CDCl!、)δ1.2 、1,3.1.5.
1.6.5.9 、7.5 ppm )を96%の収量
で得た。この化合物(4f)を10%アセトン水溶液1
00−(:けんだくし、I几120B (H+)(3F
) を加え・97℃、10時間攪拌処理し、樹脂をろ過
後ろ液を減圧下で濃縮し、シリカゲルクロマトグラフィ
ーでR,0,21(クロロホルム;メタノール、 6:
 IV/V)を示す分画を集め、目的物を82%の収量
で得た。
PM le (CDCl!,) δ1.2, 1,3.1.5.
1.6.5.9, 7.5 ppm) was obtained in 96% yield. This compound (4f) was dissolved in 10% acetone aqueous solution 1
00-(: Kendakushi, I 120B (H+) (3F
) was stirred at 97°C for 10 hours, the resin was filtered, the liquid was concentrated under reduced pressure, and silica gel chromatography was performed to obtain R,0,21 (chloroform; methanol, 6:
The fractions showing IV/V) were collected, and the desired product was obtained with a yield of 82%.

(It、り、 : 196〜198℃ 〔α。):+13.5°〜+11.2゜ymax(i’
 〕: 3500%1720PMR(DMSO)δ(p
pm) : 4.6B、5.21.7.5UVλmax
 : 222 nm(g 45700 )、287 n
m(ε4850) 元素分析(C17H1,07N): 計算値(イ)   実測値(至) N   3.95     3.99 参考例3 (3−0−(α−ナフチルカルバモイル)−P−アロー
ス(1)の合成〕 H−C=0 H−C−OH H−C−OH OH20H 1,2,5,6−ジー9−イソプロピリデン−α−♀−
アロフラノース(5,5f ) 、無水ピリジン(40
7り・α−ナフテルイソンアネー) (8,2−)を光
を連断して室温10時間攪拌反応させた後、溶媒を減圧
下で留去し、生成したンラップをンリカゲルクロマトグ
ラフイー(ベンゼン:酢酸エチル、’ 5 : I V
/V) l”l−より分画精製し、RFO,39の両分
を集め、減圧amを行い、1,2゜5.6−ジー9−イ
ソプロピリデン−3−9−(α−ナフチルカルバモイル
)−α−D −7crフラノース(ンラツプ;〔α)、
 + 71.40;νmax3300−2980−17
80 cm−” : P M R(CDCj3)δ1.
2.1.3.1.5.1.6.5.9.7.5 ppm
 )を977oの収量で得た。この化合物(4f)を1
0%アセトン水溶液100−にけんだくし、エル120
B (H+) (3t )を加え、85℃、5時間攪拌
処理し、樹脂をろ過後ろ液を減圧下で濃縮し、シリカゲ
ルクロマトグラフィーでR。
(It, Ri: 196~198℃ [α.): +13.5°~+11.2゜ymax(i'
]: 3500% 1720PMR (DMSO) δ(p
pm): 4.6B, 5.21.7.5UVλmax
: 222 nm (g 45700), 287 n
m (ε4850) Elemental analysis (C17H1,07N): Calculated value (a) Actual value (to) N 3.95 3.99 Reference example 3 (3-0-(α-naphthylcarbamoyl)-P-allose (1) Synthesis] H-C=0 H-C-OH H-C-OH OH20H 1,2,5,6-di-9-isopropylidene-α-♀-
Allofuranose (5,5f), anhydrous pyridine (40
After reacting 7ri・α-naphthalene) (8,2-) with stirring at room temperature for 10 hours under continuous light, the solvent was distilled off under reduced pressure, and the resulting wrap was subjected to phosphor gel chromatography. (benzene: ethyl acetate, '5: IV
/V) l"l-, both fractions of RFO and 39 were collected, and vacuum am was applied to obtain 1,2°5.6-di-9-isopropylidene-3-9-(α-naphthylcarbamoyl). )-α-D-7cr furanose (unlap; [α),
+71.40; νmax3300-2980-17
80 cm-”: PMR(CDCj3)δ1.
2.1.3.1.5.1.6.5.9.7.5 ppm
) was obtained in a yield of 977o. This compound (4f) is 1
Kendaku in 0% acetone aqueous solution 100-, L-120
B (H+) (3t) was added, stirred at 85°C for 5 hours, the resin was filtered, the liquid was concentrated under reduced pressure, and R was purified by silica gel chromatography.

0.27 (クロロホルム:メタノール、6:IV/V
 )を示す分画を集め、目的物を6o%の収量で得た。
0.27 (chloroform:methanol, 6:IV/V
) were collected, and the desired product was obtained in a yield of 60%.

m、p、 : 89〜91℃ 〔α、):+8.2°〜3.3゜ !/ max (z−’ ) : 3500.1720
PM几(DMSO−d、)  δ (ppm)  : 
 4.68.5.22.7.5元素分析(C17H19
0□N): 計算値(慟   実測値(イ) N    3.99    3.99 参考例4 (5−0−(α−ナフチルカルバモイル)−P−グルク
ロン酸(ff)の合成〕 H−C=0 H−C−OH HCO−Co−NH−C1゜R7 0OH 3,6−D−グルクロノラクトン(10F)を400−
の無水アセトン(=加温溶解し、lR12゛○B(l(
′+)(6f)を加え、15時間還流加熱した。反応後
、lR120B(H+)をろ別し、濃縮し、クロロホル
ムで抽出し、これを減圧留去しシロップを少竜の酢酸エ
テル1;溶かしてヘキサンを加えて結晶化を行い、1.
2−0−インプロピリデン−3,6−D−グルクロノラ
クトン(m、p。
m, p,: 89-91°C [α,): +8.2°-3.3°! / max (z-'): 3500.1720
PM (DMSO-d,) δ (ppm):
4.68.5.22.7.5 Elemental analysis (C17H19
0□N): Calculated value (Actual value (a) N 3.99 3.99 Reference example 4 (Synthesis of 5-0-(α-naphthylcarbamoyl)-P-glucuronic acid (ff)) H-C= 0 H-C-OH HCO-Co-NH-C1゜R7 0OH 3,6-D-glucuronolactone (10F) to 400-
of anhydrous acetone (=dissolved by heating, lR12゛○B(l(
'+) (6f) was added and heated under reflux for 15 hours. After the reaction, 1R120B (H+) was filtered off, concentrated, and extracted with chloroform, which was distilled off under reduced pressure, and the syrup was dissolved in Shaolong's acetic ether and added with hexane for crystallization.1.
2-0-inpropylidene-3,6-D-glucuronolactone (m, p.

120〜121℃:〔α)I) + 7.0’ ; v
 max3380.1770 crn−’)を5o%の
収量で得た。この化合物(3,3F )とα−ナフチル
イソンアネート(6,5ゴ)を無水ピリジン(40d)
l二とかし、光を遮断して6時間反応させ減圧留去して
ンラツプを得、メタノールから結晶化して1.2−0−
イソプロピリデン−5−0−(α−ナフチルカルバモイ
ル)−3,5−D−グルクロノラクトン(m、p、 1
74〜176℃;νmax3420.1800−172
0 crpr  、P M R(CDC4)δ7、日、
5.2.5.1 、4.9.1.5.1.3 ppm 
:〔α)、 + 75°)を 80%の収量で得た。こ
の化合物(3f)を1o%アセトン水溶液):けんだく
し、lR12oB(H+)(1t )を加え80℃で2
4時間加水分解し反応後樹脂をろ別し、脱色炭処理後、
減圧濃縮し、生成物を熱酢酸エチルから結晶化して5−
0−(α−ナフチルカルバモイル)−D−グルクロン酸
を80%の収量で得た。
120-121℃: [α)I) + 7.0'; v
max3380.1770 crn-') was obtained in a yield of 5o%. This compound (3,3F) and α-naphthylisonanate (6,5G) were mixed with anhydrous pyridine (40d).
1.2-0-
Isopropylidene-5-0-(α-naphthylcarbamoyl)-3,5-D-glucuronolactone (m, p, 1
74-176℃; νmax3420.1800-172
0 crpr , P M R (CDC4) δ7, day,
5.2.5.1, 4.9.1.5.1.3 ppm
: [α), +75°) was obtained in 80% yield. This compound (3f) was dissolved in a 10% acetone aqueous solution (10% acetone aqueous solution), and 1R12oB(H+) (1t) was added thereto at 80℃ for 2 hours.
After 4 hours of hydrolysis and reaction, the resin was filtered and treated with decolorizing charcoal.
Concentrate under reduced pressure and crystallize the product from hot ethyl acetate to give 5-
0-(α-naphthylcarbamoyl)-D-glucuronic acid was obtained with a yield of 80%.

mJl、:189〜190℃ 〔α、)ニー25°〜−7,5゜ W maX (cfn−” )  : 3480.17
30PMR(I)MSO−d、 )δ(9tm ) :
 8.1 %7.6 、5.6参考例5 (5−0−フェニルカルバモイル−P〜リホース(v)
の合成〕 H−C=0 夏 −C−OH H−C−OH(v) −C−OH H−C−0−Co−洲−C6H5 p−リボース(10f)・無水アセトン−無水)9/ 
−/l/混合物(1/l、 V/v) 75 mt 。
mJl,: 189~190℃ [α,) Knee 25°~-7.5゜W maX (cfn-”): 3480.17
30PMR(I)MSO-d, )δ(9tm):
8.1% 7.6, 5.6 Reference Example 5 (5-0-phenylcarbamoyl-P~rehose (v)
Synthesis] H-C=0 summer-C-OH H-C-OH (v) -C-OH H-C-0-Co-zu-C6H5 p-ribose (10f)/anhydrous acetone-anhydrous) 9/
-/l/mixture (1/l, V/v) 75 mt.

エル120B(H+)(5r )を2時間還流加熱反応
させた。樹脂をろ別し、ろ液を減圧濃縮しンラツブを得
た。さら(:、クロロホルムで抽出精製してメチル2.
3−0−イソプロピリデン−β一旦一リすンドを60%
の収1で得た。この化合物1fとフェニルイソンアネー
ト2.5tntとを30−のピリジン中、室温で10時
間攪拌しながら反応させ、溶媒な留去後、シリカゲルク
ロマトグラフィー(ベンゼン:酢酸エテル;5:1V/
V ) テRFO,65の両分を集め、98%の収量で
メチル2.3−0−イソプロピリデン−5−0−フェニ
ルカルバモイル−β−p−リボフラノシド(〔α)D−
33,6° ; y max 3420%17006n
  、PMR(CDCt3)  δ 7.4.4.9.
3.4.1.5 、1.629m )を得た。この化合
物1fを10%アセトン水溶液(二けんたくし、lR1
2OB(H+)(200++v)を加え、10時間還流
加熱した後、樹脂をろ別し、ろ液を減圧濃縮し、酢酸エ
テルから結晶化して、目的物を80%の収量で得た。
El 120B (H+) (5r) was reacted under reflux for 2 hours. The resin was filtered off, and the filtrate was concentrated under reduced pressure to obtain a lump. Further, extract and purify with chloroform to obtain methyl 2.
3-0-isopropylidene-β 60%
Obtained from Yield 1. This compound 1f and 2.5 tnt of phenylisonanate were reacted in 30-mer pyridine with stirring at room temperature for 10 hours, and after distilling off the solvent, silica gel chromatography (benzene:acetic acid ether; 5:1V/
V) Both fractions of teRFO,65 were collected and methyl 2.3-0-isopropylidene-5-0-phenylcarbamoyl-β-p-ribofuranoside ([α)D-
33,6°; y max 3420%17006n
, PMR(CDCt3) δ 7.4.4.9.
3.4.1.5, 1.629 m) was obtained. This compound 1f was dissolved in a 10% acetone aqueous solution (Nikentakushi, 1R1
After adding 2OB(H+) (200++v) and heating under reflux for 10 hours, the resin was filtered off, the filtrate was concentrated under reduced pressure, and crystallized from ethyl acetate to obtain the desired product in a yield of 80%.

m、P、:105 〜107 ℃ 〔α、)  : + 20’ 〜+ 215.3゜W 
InaX (tyy(−1) : 3460 m 34
20 s 303051700  、1230 PMR(DMSO−d、 )δ(ppm ) : 7.
4.5.02元素分析(01□H1,No、 ) :計
算値陶   実測値〜 N   5.20    5.30 参考例6 (5−0−(α−ナフチルカルバモイル)一旦−リポー
ス(旬の合成〕 H−C=0 H−C−OH (V)の調製で用いたメチル2.3−0−イソプロピリ
デン−β−■−リボフラノンド(4f)、α−ナフヂル
イソンアネート(5mA)、ピリジン(50−)を光を
遮断して15時間室温で攪拌した後、溶媒を留去し、シ
ロップとしてメチル2.3−0−イソプロピリデン−5
−2−(α−ナフtルカルパモイル)−β一旦一リすン
ド(v max 3440.1750,1240z−1
; (α〕0−36.6°: PMJCDC/3)δ7
.6.4.98.3.28.1.4.1.2 ppm 
)を100%の収量で得た。この化合物5fを10%ア
セトン水溶液(:けんたくし、lR120B(H”)(
2F)を加え、900で5時間還流加熱して反応させ、
その後、樹脂をろ別し、ろ液を濃縮し、シリカゲルカラ
ムクロマトグラフィー(クロロホルム:メタノール; 
l O: I V/V )テRFO,35ノ両分ヲ精製
し、濃縮し、酢酸エチルから結晶化して目的物を85%
の収量で得た。
m, P,: 105 ~ 107 °C [α,): + 20' ~ + 215.3 °W
InaX (tyy(-1): 3460 m 34
20 s 303051700, 1230 PMR (DMSO-d, ) δ (ppm): 7.
4.5.02 Elemental analysis (01□H1, No, ): Calculated value Actual value ~ N 5.20 5.30 Reference example 6 (5-0-(α-naphthylcarbamoyl) once-liposu ] Methyl 2 used in the preparation of H-C=0 H-C-OH (V) 3-0-isopropylidene-β-■-ribofuranondo (4f), α-naphdylisonanate (5 mA), pyridine After stirring (50-) at room temperature for 15 hours in the absence of light, the solvent was distilled off and a syrup was prepared using methyl 2.3-0-isopropylidene-5.
-2-(α-Napht-rucarpamoyl)-β once restarted (v max 3440.1750,1240z-1
; (α]0-36.6°: PMJCDC/3) δ7
.. 6.4.98.3.28.1.4.1.2 ppm
) was obtained in 100% yield. This compound 5f was dissolved in a 10% acetone aqueous solution (Kentakushi, 1R120B(H”)).
2F) and heated under reflux at 900°C for 5 hours to react.
Thereafter, the resin was filtered off, the filtrate was concentrated, and silica gel column chromatography (chloroform:methanol;
1 O: IV/V) TeRFO, 35 fractions were purified, concentrated, and crystallized from ethyl acetate to obtain 85% of the target product.
yield was obtained.

m、p、:113〜114 ℃ 〔α)D: + 14.3°〜+18.6゜νmax 
(儒−’):3450.3400.30301PMR(
DM80−d、) a (pPm) : 7.4.5.
02元素分析(C1,H工、No、): 計算値(至)   実測値(至) N    4,39    4.34 参考例7 〔化合物1−11の酸素ラジカル生成能〕5×10 M
のブトクロ−4C溶液(pH8,0゜0.2Mリン酸緩
衝液)(二化合物1 mM (10−”M)を溶解し、
直ちC:、25℃で550nm(7)吸光度の増加を調
べたところ・ I : 6.95XIO−4;1:2.
85X10     、   夏  :5,62Xl 
 ○    。
m, p,: 113~114°C [α)D: +14.3°~+18.6°νmax
(Confucian-'): 3450.3400.30301PMR(
DM80-d,) a (pPm): 7.4.5.
02 elemental analysis (C1, H engineering, No.): Calculated value (to) Actual value (to) N 4,39 4.34 Reference example 7 [Oxygen radical generation ability of compound 1-11] 5 × 10 M
Butoclo-4C solution (pH 8, 0° 0.2M phosphate buffer) (1 mM (10-''M) of the two compounds was dissolved,
Immediately C:, when the increase in absorbance at 550 nm (7) at 25°C was examined, I: 6.95XIO-4; 1:2.
85X10, summer: 5,62Xl
○.

ff:1.44X10  、V:5,67X10  。ff: 1.44X10, V: 5,67X10.

w:3,09XIO(Δλ550/m1n)という結果
が得られた。コントロールとして用いたブドウ塘(、H
−グルコース)、P−リボースはそれぞれ0.75 X
 I O−’ #よび1.5 X I O−’ (20
%エタノール溶液)を示した。
A result of w: 3,09XIO (Δλ550/m1n) was obtained. Grape dumplings (,H
-glucose) and P-ribose are each 0.75
I O-'# and 1.5 X I O-' (20
% ethanol solution).

参考例8 〔化合物T、VおよびMのインヴイトロ核酸切断活性〕 化合物1、Vおよび可をりん酸緩衝液中(pH7,2)
 、二重鎖のφx 174 DNA 200 nf 、
糖1 mM、 Cu” 10 pMを37℃、3時間処
理し、−木調の一箇所切断(Form I )および直
鎖状DNA(Forml )の生成を調べたところ、そ
れぞれ、18.0%; 86.2.8.4%; 84.
3.5.8%であった。
Reference Example 8 [In vitro nucleic acid cleavage activity of compounds T, V and M] Compounds 1, V and K in phosphate buffer (pH 7, 2)
, double-stranded φx 174 DNA 200 nf,
When treated with 1 mM of sugar and 10 pM of Cu'' at 37°C for 3 hours, the production of wood-like single-site cleavage (Form I) and linear DNA (Forml) was examined, and the results were 18.0%; 86.2.8.4%; 84.
It was 3.5.8%.

実施例1 〔化合物1〜頁のインヴイトロウィルス不活化作用〕 化合物i〜Mのインヴイトロウィルス不活化作用を、タ
バコモザイクウィルスおよびバクテリオファージφ×1
74を用いて検討した。前者はリン酸緩衝液(0,2M
、pH8,1)中、糖濃度10” M 、 Cu” I
 Q−’ Mを用い、37℃、3時間ウィルスと反応さ
せ、ウィルスの生存率(イ)を、N、タバヵムを用いる
生葉法で検定を行った。
Example 1 [In vitro virus inactivation effect of compounds 1 to 1 page] The in vitro virus inactivation effect of compounds i to M was demonstrated using tobacco mosaic virus and bacteriophage φ×1.
The study was conducted using 74. The former is a phosphate buffer (0.2M
, pH 8.1), sugar concentration 10"M, Cu"I
Q-' M was used to react with the virus at 37°C for 3 hours, and the survival rate (a) of the virus was assayed by the fresh leaf method using N and tabacum.

後者はリン酸緩衝液中、10−3Mの糖濃度、Cu10
MでφX174を37℃、3時間処理し・処理0時間(
二対するプラークの生成率を生存率(イ)とした。化合
物1、■、■のTMVに対する不活化斃は、生存率がそ
れぞれ51.14および60%という結果で示された。
The latter was carried out at a sugar concentration of 10 −3 M in phosphate buffer, Cu10
φX174 was treated with M at 37℃ for 3 hours, and 0 hours of treatment (
The rate of plaque formation for the two was defined as the survival rate (a). The inactivation of Compounds 1, ■, and ■ against TMV was demonstrated with survival rates of 51.14% and 60%, respectively.

一方、化合物■、V、WはφX174に対してそれぞれ
33.8.38.4 、および44.2%を示した。
On the other hand, compounds ①, V, and W showed 33.8%, 38.4%, and 44.2% of φX174, respectively.

以上3つのインヴイトロ反応性および生物活性の結果←
参考例6.7及び実施例1)は、これらの誘導体が未置
換の451(アルドヘキソース)(二はみられない、又
は未置換の場合より大きい反応性又は生物活性を有する
ことを示している。
The above three in vitro reactivity and biological activity results←
Reference Example 6.7 and Example 1) show that these derivatives have greater reactivity or biological activity than the unsubstituted 451 (aldohexose) (2 is absent or unsubstituted). .

以上that's all

Claims (2)

【特許請求の範囲】[Claims] (1)¥O¥−アリールカルバモイルアルドースを有効
成分とするウィルス不活化剤。
(1) A virus inactivator containing ¥O¥-arylcarbamoylaldose as an active ingredient.
(2)アルドース部が5炭糖又は6炭糖であることを特
徴とする第1項記載のウィルス不活化剤。
(2) The virus inactivating agent according to item 1, wherein the aldose moiety is a pentose or a hexose.
JP19126285A 1985-08-30 1985-08-30 Virus inactivator Granted JPS6251618A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP19126285A JPS6251618A (en) 1985-08-30 1985-08-30 Virus inactivator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19126285A JPS6251618A (en) 1985-08-30 1985-08-30 Virus inactivator

Publications (2)

Publication Number Publication Date
JPS6251618A true JPS6251618A (en) 1987-03-06
JPH03842B2 JPH03842B2 (en) 1991-01-09

Family

ID=16271609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP19126285A Granted JPS6251618A (en) 1985-08-30 1985-08-30 Virus inactivator

Country Status (1)

Country Link
JP (1) JPS6251618A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092907A3 (en) * 2004-03-26 2006-04-27 Ranbaxy Lab Ltd Monosaccharide derivatives as anti-cancer and anti-inflammatory agents
WO2006111783A1 (en) * 2005-04-19 2006-10-26 Ranbaxy Laboratories Limited Monosaccharide derivatives as anti-inflammatory and/or anti-cancer agents
US7790689B2 (en) 2006-05-30 2010-09-07 Ranbaxy Laboratories Limited Monosaccharide derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50117744A (en) * 1974-03-06 1975-09-16

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50117744A (en) * 1974-03-06 1975-09-16

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092907A3 (en) * 2004-03-26 2006-04-27 Ranbaxy Lab Ltd Monosaccharide derivatives as anti-cancer and anti-inflammatory agents
WO2006111783A1 (en) * 2005-04-19 2006-10-26 Ranbaxy Laboratories Limited Monosaccharide derivatives as anti-inflammatory and/or anti-cancer agents
US7790689B2 (en) 2006-05-30 2010-09-07 Ranbaxy Laboratories Limited Monosaccharide derivatives

Also Published As

Publication number Publication date
JPH03842B2 (en) 1991-01-09

Similar Documents

Publication Publication Date Title
RU2041234C1 (en) CRYSTALLINE 2-O-α-D-GLUCOPYRANOZYL-L-ASCORBIC ACID AND METHOD FOR ITS PRODUCTION
EP2828275B1 (en) Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
Glaudemans et al. Syntheses with Partially Benzylated Sugars. III. 1 A Simple Pathway to a “cis-Nucleoside,” 9-β-D-Arabinofuranosyladenine (Spongoadenosine)
EP2280987B1 (en) Triterpene saponins, methods of synthesis, and uses thereof
DK163585B (en) RETINOIDCARBOXYLSYRE-MONO AND -DISACCHARIDESTERE, THESE ESTERS FOR USE AS MEDICINES IN PARTICULAR FOR THE TREATMENT OF neoplasia ACNE OR PSORIASIS, METHOD FOR PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THEM ESTERS AND USE OF Estonians FOR PRODUCTION OF A MEANS treatment of neoplasia, ACNE OR PSORIASIS
JP2921990B2 (en) Colchicine derivatives and their therapeutic use
JPS6251618A (en) Virus inactivator
EP0063106A1 (en) Process for preparing high purity ursodeoxycholic acid
DE3508356C2 (en)
DK141170B (en) Process for Preparation of 9.3 ", 4" Trialkanoyl SF-837 M1 Derivatives.
AU2007291508B2 (en) Preparation and purification of mupirocin calcium
JPH10287617A (en) New diterpenes and antivirus agent containing diterpenes as active ingredient
EP0445021A2 (en) Tris acyl-2",3",4'ethylidene-4",6"-beta-D-glucopyranosides, their production and use in the synthesis of ethylidene-4",6"-beta-D-glucopyranosides of epipodophyllotoxin
Khan et al. Enzymic regioselective hydrolysis of peracetylated reducing disaccharides, specifically at the anomeric centre: Intermediates for the synthesis of oligosaccharides.
AU2017258850B2 (en) Triterpene saponins, methods of synthesis, and uses thereof
WO1994014829A1 (en) Etoposide derivatives, process for their preparation, their use as a drug and in the preparation of a drug for treating cancer
JPH04500677A (en) A special method for the synthesis of novel dithiocarbamate esters by replacing the hydroxylated sites of mono- or polyhydroxylated molecules, the products obtained by this method and their applications.
CN102381972A (en) Propofol hydroxy acid ester compound with ester structure terminal and preparation method and application thereof
US3660498A (en) Pentol derivatives
DE69323998T2 (en) PHARMACEUTICAL ACTIVE FLAVILIUM COMPOUNDS
FR2688003A1 (en) Nucleoside derivatives, their preparation and their biological applications
JPS63440B2 (en)
Ueda et al. Sequential Site-Selective Functionalization: A Strategy for Total Synthesis of Natural Glycosides
FR2510574A1 (en) 2 'MODIFIED KANAMYCINS, PROCESS FOR OBTAINING THEM AND THEIR USE AS ANTIBACTERIAL AGENTS
US5508390A (en) Diterpenes having immunomodulatory action